MetaVia Inc. — Form 8-K
Filed November 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
MetaVia announced completion of the final patient visit in its Phase 1 Part 3A study of DA-1726 (a GLP-1/glucagon dual agonist), with the treatment period extended from 16 to 24 weeks at 48 mg weekly based on encouraging safety/tolerability. Part 3B interim data showed statistically significant 68.1% placebo-adjusted reduction in liver fat, 13.5% weight loss, and improved glycemic control. Full Part 3A and 3B data expected Q1 2027; Phase 2 study in MetALD/ALD planned for H2 2027 with up to 150 patients.
Why this rating
Clinical trial milestone in lead program is material for a $3M-market-cap biotech. Positive interim efficacy (68% liver-fat reduction) and decision to extend dosing strengthen near-term Phase 2 runway, reducing development risk—major value driver for pre-revenue clinical-stage firm.
Tradability signal
NO TRADE
No trade: only ~$72k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.26 ▲ 2.44% | at our read · unknown $1.23 | +10 min · unknown $1.26 ▲ 2.85% | +30 min · unknown $1.32 ▲ 7.32% | +1 hr · unknown $1.31 ▲ 6.50% | +4 hrs · unknown $1.23 ▲ 0.00% |
The stock had already moved -2.38% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.